NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.368) was uploaded to the NHS England Website on Thursday 3, July 2025.
The following changes have been introduced:
Fruquintinib (FRU1)
Fruquintinib for patients with either metastatic or locally advanced and inoperable colorectal cancer who have received 2 or more prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies with or without anti-VEGF agents and/or anti- EGFR-based agents AND for whom the combination of trifluridine plus tipiracil and bevacizumab is unsuitable where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Atezolizumab (ATE10)
Atezolizumab monotherapy for adjuvant treatment after complete tumour resection in adult patients with UICC/AJCC 8th edition stage IIB or IIIA or N2 only IIIB non-small cell lung cancer and whose disease is all of the following: has PD-L1 expression on ≥50% of tumour cells, is not EGFR mutant or ALK- positive and has not progressed on recently completed adjuvant platinum-based chemotherapy where the following criteria have been met
Treatment criterion (#5) updated
Regorafenib (REG3)
For patients with either metastatic or locally advanced and inoperable colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy and anti-EGFR-based treatment where the following criteria have been met
Treatment criteria (#6, 7, 11 and 14) updated
Durvalumab in combination with platinum-containing chemotherapy (carboplatin and paclitaxel) (DUR5)
For the 1st line treatment of mismatch repair deficient (dMMR) or microsatellite instability-high endometrial carcinoma in adult patients who have recurrent or primary advanced disease and who are not candidates for potentially curative surgery or radiotherapy or chemoradiotherapy but are eligible for systemic therapy where the following criteria have been met
Date moving into routine commissioning updated